Anti-Human IgE/IGHE Reference Antibody (Omalizumab, RUO) (HV064016)

Datasheet Share product Copy info

Price(USD): $

Spec:

100ug
1mg

Number:

Overview
Images
References
Datasheet
SDS

Overview

Catalog No.

HV064016

Description

Omalizumab (HV064016) is a research-grade recombinant antibody targeting Ig epsilon chain C region. Produced in mammalian cells with native-like glycosylation.

Highlights

●Research Grade — For PK/PD studies, assay development, and ADA research.
●Native Glycosylation — Mammalian expression ensures native-like patterns.

Species reactivity

Human

Applications

ELISA, Bioactivity: FACS, Functional assay, Research in vivo

Host species

Humanized

Isotype

IgG1-kappa

Expression system

Mammalian Cells

Clonality

Monoclonal

Target

Ig epsilon chain C region, IGHE, Ig epsilon chain C region ND, Immunoglobulin heavy constant epsilon

Endotoxin level

Please contact the lab for this information.

Purity

>95% purity as determined by SDS-PAGE.

Purification

Protein A/G purified from cell culture supernatant.

Accession

CAS: 242138-07-4

Form

Liquid

Storage buffer

0.01M PBS, pH 7.4.

Please refer to the specific buffer information in the hardcopy of datasheet or the lot-specific COA.

Product Usage Information

Application	Dilution
ELISA	1:2000-1:20000

Stability and Storage

Use a manual defrost freezer and avoid repeated freeze-thaw cycles. Store at 4°C for short-term storage (1-2 weeks). Store at -20°C for up to 12 months. For long-term storage, store at -80°C.

Alternate Names

IGE25, olizumab, pSVIE26, rhuMab-E25, 242138-07-4, MaE11

Background

Immunoglobulin heavy constant epsilon (IgE/IGHE) is a ~59 kDa protein. Constant region of immunoglobulin heavy chains. Immunoglobulins, also known as antibodies, are membrane-bound or secreted glycoproteins produced by B lymphocytes. In the recognition phase of humoral immunity, the membrane-bound immunoglobulins serve as receptors which, upon binding of a specific antigen, trigger the clonal expansion and differentiation of B lymphocytes into immunoglobulins-secreting plasma cells. Secreted immunoglobulins mediate the effector phase of humoral immunity, which results in the elimination of bound antigens. The antigen binding site is formed by the variable domain of one heavy chain, together with that of its associated light chain.

1. Schroeder, HW. et al. (2010) The Journal of allergy and clinical immunology 125, S41-52. PMID: 20176268

2. McHeyzer-Williams, M. et al. (2011) Nature reviews. Immunology 12, 24-34. PMID: 22158414

3. Teng, G. et al. (2007) Annual review of genetics 41, 107-20. PMID: 17576170

Note

For research use only. Not suitable for clinical or therapeutic use.

Images

Bioactivity

SEC-HPLC detection for Research Grade Omalizumab.
SDS-PAGE

SDS-PAGE for Research Grade Omalizumab.

References

Datasheet

Anti-Human IgE/IGHE Reference Antibody (Omalizumab, RUO).pdf

Download SDS PDF

Formula

Mass (g) = Concentration (mol/L) × Volume (L) × MW (g/mol)

Enter any 2 of Mass, Concentration, Volume + Molecular Weight to solve for the unknown.

Mass

Concentration

Volume

Molecular Weight *

g/mol

Formula

C₁ × V₁ = C₂ × V₂

Enter any 3 of the 4 values to solve for the unknown.

Stock Solution

C₁ (Stock Conc.)

V₁ (Stock Vol.)

Working Solution

C₂ (Working Conc.)

V₂ (Working Vol.)

Recombinant Proteins

Antibodies

Assay Kits

Anti-Human IgE/IGHE Reference Antibody (Omalizumab, RUO) (HV064016)

Overview

Images

References

Datasheet

SDS

Quick access

Contact Us